ライフサイエンスコーパス: pneumococcal pneumonia

1 tly reported as a useful diagnostic tool for pneumococcal pneumonia.

2 ssion and aids neutrophil recruitment during pneumococcal pneumonia.

3 T3 activation augmented host defense against pneumococcal pneumonia.

4 s, thus promoting early bacterial killing in pneumococcal pneumonia.

5 showed reduced virulence in a mouse model of pneumococcal pneumonia.

6 improved protection against otitis media and pneumococcal pneumonia.

7 oman presents with severe community-acquired pneumococcal pneumonia.

8 thesis confers resistance to s/s mice during pneumococcal pneumonia.

9 ermine the role of this signaling pathway in pneumococcal pneumonia.

10 rial superinfections, particularly secondary pneumococcal pneumonia.

11 g" with PPV in adults who had recovered from pneumococcal pneumonia.

12 anism underlying the high early mortality of pneumococcal pneumonia.

13 okine is essential to surviving experimental pneumococcal pneumonia.

14 etermine the roles of these cytokines during pneumococcal pneumonia.

15 ystem by a DcR3 analog (DcR3-a) in mice with pneumococcal pneumonia.

16 improves clearance of bacteria in mice with pneumococcal pneumonia.

17 e surface of the pneumococcus in vivo during pneumococcal pneumonia.

18 proposed vaccine antigen can protect against pneumococcal pneumonia.

19 es varied with different case definitions of pneumococcal pneumonia.

20 e of blood lytA quantification in diagnosing pneumococcal pneumonia.

21 ced TNF is important for host defense during pneumococcal pneumonia.

22 is factor-alpha (TNF) in the pathogenesis of pneumococcal pneumonia.

23 Welders are at increased risk of pneumococcal pneumonia.

24 gnaling in the liver is important to control pneumococcal pneumonia.

25 ABCD) with the wild type in a mouse model of pneumococcal pneumonia.

26 POSTN as new players in the pathogenesis of pneumococcal pneumonia.

27 ore, liposomes protect mice against invasive pneumococcal pneumonia.

28 the effect of thrombocytopenia during murine pneumococcal pneumonia.

29 evidence for an interaction between RSV and pneumococcal pneumonia.

30 e presentation and outcomes of patients with pneumococcal pneumonia.

31 mice in vitro and in an established model of pneumococcal pneumonia.

32 it did not impact on bacterial loads during pneumococcal pneumonia.

33 njury and inflammatory responses observed in pneumococcal pneumonia.

34 eographic subpopulations at greater risk for pneumococcal pneumonia.

35 swabs may be preferable for the diagnosis of pneumococcal pneumonia.

36 promise as an adjunct therapeutic avenue for pneumococcal pneumonia.

37 colonization density and, in turn, invasive pneumococcal pneumonia.

38 with efficient protection against secondary pneumococcal pneumonia.

39 to impaired survival of mice suffering from pneumococcal pneumonia.

40 ologous strain in a murine model of invasive pneumococcal pneumonia.

41 term survival of patients who recovered from pneumococcal pneumonia.

42 chanism of alveolar macrophage cell death in pneumococcal pneumonia.

43 Pdelta in host defense in community-acquired pneumococcal pneumonia.

44 inflammatory, and noxious stimuli, including pneumococcal pneumonia.

45 eumococcal pneumonia were 58.3% (code 481.0, pneumococcal pneumonia), 20.4% (38.0, streptococcal sept

46 d controls) showed a reduced survival during pneumococcal pneumonia (27% vs 75% among controls; p = 0

47 more sensitive for urine from patients with pneumococcal pneumonia (89.8%) than for urine from patie

48 36, we sought to examine the role of CD36 in pneumococcal pneumonia, a major cause of morbidity and m

49 In pneumococcal pneumonia, a strong local inflammatory cyto

50 usted OR, 1.7; 95% CI, 1.1-2.6) and invasive pneumococcal pneumonia (adjusted OR, 2.3; 95% CI, 1.3-4.

51 t of the programme on rates of all-cause and pneumococcal pneumonia admissions.

52 ds were tested in a mouse model of secondary pneumococcal pneumonia after influenza.

53 za-infected wild-type mice cleared secondary pneumococcal pneumonia after pulmonary administration of

54 R), and urine antigen testing for diagnosing pneumococcal pneumonia among 149 adults with community-a

55 enza was also associated with an increase in pneumococcal pneumonia among children aged 1-2 y (AP: 3.

56 reaction (PCR) on blood in the diagnosis of pneumococcal pneumonia among children from 7 low- and mi

57 redictive values (NPV) of specific codes for pneumococcal pneumonia among hospitalized patients with

58 ion, high colonization density, and invasive pneumococcal pneumonia among patients hospitalized with

59 there was an outbreak of multidrug-resistant pneumococcal pneumonia among the residents of a nursing

60 e, as indicated by 100% survival from lethal pneumococcal pneumonia and 10 000-fold greater efficienc

61 from 14 (27%) of 51 patients with bacteremic pneumococcal pneumonia and 11 (37%) of 30 with nonbacter

62 Rate ratios for pneumococcal pneumonia and all-cause pneumonia demonstra

63 model, we projected the future incidence of pneumococcal pneumonia and associated healthcare utiliza

64 garette smoke exposure increases the risk of pneumococcal pneumonia and defines a novel cellular mech

65 f necrotizing changes in adult patients with pneumococcal pneumonia and examined the severity of infe

66 cause of death in childhood from ALRI, after pneumococcal pneumonia and Haemophilus influenzae type b

67 of IL-22 signaling during a murine model of pneumococcal pneumonia and improvement of bacterial burd

68 vaccine also reduced admissions for invasive pneumococcal pneumonia and non-invasive pneumococcal or

69 Here, we demonstrate that pneumococcal pneumonia and other severe infections incre

70 nd Ply is essential for the establishment of pneumococcal pneumonia and sepsis in a murine model of i

71 Using a sickle cell mouse model of pneumococcal pneumonia and sepsis, administration of hyd

72 ds and improved survival in a mouse model of pneumococcal pneumonia and sepsis.

73 ut PCV13 effectiveness against nonbacteremic pneumococcal pneumonia and the magnitude of potential in

74 rdiac tissue from six adult NHPs with severe pneumococcal pneumonia and three uninfected control anim

75 r their abilities to attenuate the course of pneumococcal pneumonia and to prevent colonization of th

76 ncreased for up to 10 years after documented pneumococcal pneumonia and was greater in proportion to

77 invasive pneumococcal disease, non-invasive pneumococcal pneumonia, and empyema (all coded by Intern

78 timing of the average seasonal peak of RSV, pneumococcal pneumonia, and pneumococcal septicemia.

79 During pneumococcal pneumonia, antibacterial defense requires t

80 ted with respect to effects on postinfluenza pneumococcal pneumonia as measured by bacterial growth,

81 Pdelta(-/-) mice are relatively resistant to pneumococcal pneumonia, as indicated by delayed and redu

82 and V70 sequence accelerated development of pneumococcal pneumonia, as reflected by increased levels

83 c contributions to the early pathogenesis of pneumococcal pneumonia at different stages of infection

84 rotein of 12 kDa impairs host defense during pneumococcal pneumonia at the primary site of infection

85 gest that IRAK-M impairs host defense during pneumococcal pneumonia at the primary site of infection

86 identified factors associated with invasive pneumococcal pneumonia, bacterial loads, and death.

87 een in 6.6% of a large series of adults with pneumococcal pneumonia but were often overlooked on init

88 airway pneumococcal colonization density and pneumococcal pneumonia, but data in children are limited

89 t an unfavorable role in host defense during pneumococcal pneumonia by a mechanism independent of deg

90 We measured the burden of pneumococcal pneumonia by applying the proportion of pne

91 ibutes to the early pathogenesis of invasive pneumococcal pneumonia by facilitating intrapulmonary ba

92 uring 2007 to 2009 with laboratory-confirmed pneumococcal pneumonia by using monoclonal antibodies an

93 al (NP) swabs distinguish community-acquired pneumococcal pneumonia (CAP) from asymptomatic colonizat

94 umonia and 11 (37%) of 30 with nonbacteremic pneumococcal pneumonia contained IgG to CPS of the infec

95 certain serotype-specific antibodies against pneumococcal pneumonia could be associated with modulati

96 The seasonality of invasive pneumococcal pneumonia could be due to increased suscept

97 ickle cell mice improved their survival from pneumococcal pneumonia, counteracting the abnormally ele

98 Pneumococcal pneumonia declined from 2.9 to 1.2 cases pe

99 nd bacterial replication in a mouse model of pneumococcal pneumonia, despite being necessary for clea

100 vailable specimen may significantly increase pneumococcal pneumonia diagnoses in adults.

101 of NA inhibition was to limit the extent of pneumococcal pneumonia during early infection.

102 , and the demand for healthcare services for pneumococcal pneumonia, especially inpatient capacity, w

103 p to one-third of patients hospitalized with pneumococcal pneumonia experience major adverse cardiac

104 pital admission, patients with nonbacteremic pneumococcal pneumonia had higher levels of serum anti-p

105 ect 2003-2009, we quantified the increase in pneumococcal pneumonia hospitalization rates above a sea

106 Annual pneumococcal pneumonia hospitalization rates per 100 000

107 ng >700,000 RSV hospitalizations and >16,000 pneumococcal pneumonia hospitalizations in 36 states (19

108 nd 2040, as the population increases by 38%, pneumococcal pneumonia hospitalizations will increase by

109 emic had a significant impact on the rate of pneumococcal pneumonia hospitalizations, with the magnit

110 These results indicate that during pneumococcal pneumonia, IL-10 attenuates the proinflamma

111 During pneumococcal pneumonia, IL-6 down-regulates the activati

112 ssay has favorable accuracy for diagnosis of pneumococcal pneumonia in adult patients with CAP; this

113 iae is the most common bacterial etiology of pneumococcal pneumonia in adults worldwide.

114 D may become a new standard for detection of pneumococcal pneumonia in adults.

115 h a significant increase in the incidence of pneumococcal pneumonia in children aged <1 y (attributab

116 had poor diagnostic accuracy for diagnosing pneumococcal pneumonia in children in 9 African and Asia

117 lating factor (G-CSF) on the pathogenesis of pneumococcal pneumonia in cirrhosis.

118 y PMNL, G-CSF does not protect against fatal pneumococcal pneumonia in cirrhotic rats.

119 s limited diagnostic utility for identifying pneumococcal pneumonia in individual children, but may b

120 ential benefit of TRAIL-based therapy during pneumococcal pneumonia in mice.

121 The seriousness of pneumococcal pneumonia in mouse models has been shown to

122 and that galectin-3 reduces the severity of pneumococcal pneumonia in part by augmenting neutrophil

123 coccal PCR on blood for diagnosing childhood pneumococcal pneumonia in the 7 low- and middle-income c

124 Accurate diagnosis of pneumococcal pneumonia in the acute-care setting remains

125 e I IFNs controlled RANTES production during pneumococcal pneumonia in vivo.

126 Clinical Modification (ICD-9-CM) to estimate pneumococcal pneumonia incidence and vaccine efficacy.

127 icantly by clinical presentation: bacteremic pneumococcal pneumonia incidence peaked in late winter,

128 Platelets play a protective role during pneumococcal pneumonia independent of their aggregation.

129 s influenza pandemics, we evaluated invasive pneumococcal pneumonia (IPP) rates during the 2009 influ

130 Weekly rates of invasive pneumococcal pneumonia (IPP) were obtained from the Dani

131 ne the role of IRAK-M in host defense during pneumococcal pneumonia, IRAK-M- deficient and wild-type

132 Pneumococcal pneumonia is a leading cause of death and a

133 Pneumococcal pneumonia is a life-threatening disease wit

134 Diagnosis of pneumococcal pneumonia is complicated by the lack of a d

135 Pneumococcal pneumonia is concentrated among the elderly

136 Hypersusceptibility of welders to pneumococcal pneumonia is in part mediated by the capaci

137 coding data to identify laboratory-confirmed pneumococcal pneumonia is not known.

138 Moreover, pneumococcal pneumonia is the most common opportunistic

139 In a murine model of pneumococcal pneumonia, MARCO(-/-) mice displayed an imp

140 ion antibiotic therapy for severe bacteremic pneumococcal pneumonia may reduce mortality.

141 compared between microbiologically confirmed pneumococcal pneumonia (MCPP) cases, cases confirmed for

142 Microbiologically confirmed pneumococcal pneumonia (MCPP) was confirmed by detection

143 among cases with microbiologically confirmed pneumococcal pneumonia (MCPP), cases without a confirmed

144 During pneumococcal pneumonia, Miwi2-deficient mice exhibited i

145 ligation and puncture (CLP) model and in the pneumococcal pneumonia model of sepsis.

146 In 351 cases of pneumococcal pneumonia, necrosis was reported in no (0%)

147 During pneumococcal pneumonia, NF-kappaB proteins translocate t

148 nia (one [1%] patient in the placebo group), pneumococcal pneumonia (one [1%] in the tralokinumab eve

149 Lung tissue of patients who had died from pneumococcal pneumonia or a nonpulmonary cause was stain

150 olysin IgG than did patients with bacteremic pneumococcal pneumonia or uninfected control subjects.

151 V13 on CAP, pleural effusion, and documented pneumococcal pneumonia, particularly cases due to PCV13

152 of PCV13 on a number of clinical aspects of pneumococcal pneumonia (PP) in children has not been rep

153 PP and could be used to improve estimates of pneumococcal pneumonia prevalence in childhood pneumonia

154 Protection against pneumococcal pneumonia relies on successful regulation o

155 ccess of the pneumococcal conjugate vaccine, pneumococcal pneumonia remains a significant clinical pr

156 Mortality from pneumococcal pneumonia remains high despite antibiotic t

157 oria engendered by the improved prognosis of pneumococcal pneumonia resulting from therapeutic advanc

158 treated male mice show greater resistance to pneumococcal pneumonia, seen as greater bacterial cleara

159 RSV and pneumococcal pneumonia shared a distinctive spatiotempor

160 treated mice died significantly earlier from pneumococcal pneumonia than control mice (p < 0.05).

161 IL-6-/- mice died significantly earlier from pneumococcal pneumonia than did IL-6+/+ mice (P < .05).

162 how neutrophils are recruited to the lung in pneumococcal pneumonia, the ability of pneumococcal comp

163 During pneumococcal pneumonia, the human airway epithelium is e

164 g injury model, but in oleic acid injury and pneumococcal pneumonia, there were no sustained oxygenat

165 mean lytA rtPCR copy number in patients with pneumococcal pneumonia was 6.0 log(10) copies/mL, compar

166 ble analysis among colonized cases, invasive pneumococcal pneumonia was associated with HIV (adjusted

167 ow PCV13 effectiveness against nonbacteremic pneumococcal pneumonia was assumed or when greater child

168 tandard, a composite diagnostic standard for pneumococcal pneumonia was considered positive in South

169 ffects of infection were analyzed in detail, pneumococcal pneumonia was found to alter the expression

170 Because pneumococcal pneumonia was prevalent during previous inf

171 complement properties to the pathogenesis of pneumococcal pneumonia, we compared the in vivo effects

172 contribution of PMNs to host defense against pneumococcal pneumonia, we determined the effect of the

173 tions for patients with laboratory-confirmed pneumococcal pneumonia were 58.3% (code 481.0, pneumococ

174 . pneumoniae) causes high early mortality in pneumococcal pneumonia, which is characterized by acute

175 Absent intervention, the total cost of pneumococcal pneumonia will increase by $2.5 billion ann

176 Pneumococcal pneumonia with pleural effusion was associa

177 at was associated with recurrent episodes of pneumococcal pneumonia with sepsis and other infections

178 ammation and alveolar barrier dysfunction in pneumococcal pneumonia without compromising host defence